3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Germ Cell Cancer
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lung Neoplasms
1
Hip Fractures
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
20
Nivolumab
10
Cyclophosphamide
10
atezolizumab
6
Specimen Handling
6
fludarabine
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
Ipilimumab
4
Bevacizumab
4
lenvatinib
3
X-Rays
3
Trastuzumab
3
Paclitaxel
3
Oxaliplatin
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
ulixertinib
2
sargramostim
2
poly ICLC
2
epacadostat
2
enzalutamide
2
durvalumab
2
cemiplimab
2
budigalimab
2
avelumab
2
aldesleukin
2
aflibercept
2
Sirolimus
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Hematologic Tests
×
Gynecologic
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled